CY1124635T1 - Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα - Google Patents
Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεαInfo
- Publication number
- CY1124635T1 CY1124635T1 CY20201100589T CY201100589T CY1124635T1 CY 1124635 T1 CY1124635 T1 CY 1124635T1 CY 20201100589 T CY20201100589 T CY 20201100589T CY 201100589 T CY201100589 T CY 201100589T CY 1124635 T1 CY1124635 T1 CY 1124635T1
- Authority
- CY
- Cyprus
- Prior art keywords
- active agent
- pharmaceutical compositions
- spray
- particle size
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχονται στο παρόν ξηρές φαρμακευτικές συνθέσεις κατάλληλες για διαβλεννογονική παράδοση, που περιέχουν ξηρά σωματίδια, όπως ξηρανθέντα με ψεκασμό σωματίδια, που περιλαμβάνουν νανοσωματίδια φαρμακευτικώς δραστικού παράγοντα, συνδετικό υλικό και φαρμακευτικώς αποδεκτό φορέα, όπου τα νανοσωματίδια δραστικού παράγοντα έχουν διάμετρο μέσου μεγέθους σωματιδίων πριν την επεξεργασία μικρότερη από περίπου 1 μm, και όπου ως και 10% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίων μικρότερο από 10 μm• τουλάχιστον το 50% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίου τουλάχιστον περίπου 15 μm• και τουλάχιστον το 90% των ξηρανθέντων με ψεκασμό σωματιδίων έχουν μέγεθος σωματιδίων ως περίπου 55 μm. Παρέχονται επίσης μέθοδοι για την παρασκευή τέτοιων φαρμακευτικών συνθέσεων και θεραπευτικών μεθόδων που περιλαμβάνουν διαβλεννογονική χορήγηση των συνθέσεων, όπως ενδορινικά ή ενδοκολπικά, ή με άλλες οδούς χορήγησης.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772095P | 2013-03-04 | 2013-03-04 | |
| PCT/US2014/019833 WO2014137877A1 (en) | 2013-03-04 | 2014-03-03 | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124635T1 true CY1124635T1 (el) | 2022-03-24 |
Family
ID=47901822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100589T CY1124635T1 (el) | 2013-03-04 | 2020-06-25 | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10695295B2 (el) |
| EP (1) | EP2964199B1 (el) |
| JP (1) | JP6564708B2 (el) |
| CN (1) | CN105307639B (el) |
| AU (1) | AU2014226192B2 (el) |
| BR (1) | BR112015021525B1 (el) |
| CA (1) | CA2901015A1 (el) |
| CY (1) | CY1124635T1 (el) |
| DK (1) | DK2964199T3 (el) |
| ES (1) | ES2804702T3 (el) |
| HR (1) | HRP20201103T1 (el) |
| HU (1) | HUE050050T2 (el) |
| IL (1) | IL240867B (el) |
| LT (1) | LT2964199T (el) |
| MX (1) | MX2015011624A (el) |
| PL (1) | PL2964199T3 (el) |
| PT (1) | PT2964199T (el) |
| RS (1) | RS60481B1 (el) |
| RU (1) | RU2715714C2 (el) |
| SI (1) | SI2964199T1 (el) |
| WO (1) | WO2014137877A1 (el) |
| ZA (1) | ZA201505852B (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105307639B (zh) | 2013-03-04 | 2020-06-30 | 博赏医药卢森堡责任有限公司 | 包含与载体颗粒结合的活性剂纳米颗粒的干药物组合物 |
| WO2018025089A2 (en) | 2016-08-05 | 2018-02-08 | Shin Nippon Biomedical Laboratories, Ltd. | Pharmaceutical compositions |
| WO2018213452A1 (en) * | 2017-05-19 | 2018-11-22 | Jackson Milton S | Appetite suppressant |
| JP7453770B2 (ja) | 2019-10-25 | 2024-03-21 | 松本油脂製薬株式会社 | 複合粒子及びその製造方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| FR2575678B1 (fr) | 1985-01-04 | 1988-06-03 | Saint Gobain Vitrage | Ejecteur pneumatique de poudre |
| DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| WO1997031626A1 (fr) * | 1996-02-27 | 1997-09-04 | Teijin Limited | Composition pulverulente destinee a une adminstration nasale |
| CA2341732C (en) | 1998-08-26 | 2008-08-19 | Teijin Limited | Powder composition for nasal administration |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| JP2003523954A (ja) | 1999-12-08 | 2003-08-12 | ファルマシア コーポレイション | 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物 |
| JP4721212B2 (ja) | 2001-07-05 | 2011-07-13 | 株式会社新日本科学 | インスリンの経鼻投与用組成物 |
| CN1176649C (zh) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| ATE329594T1 (de) | 2003-01-31 | 2006-07-15 | Orexo Ab | Schnell wirkende pharmazeutische zusammensetzung |
| WO2004073729A1 (ja) | 2003-02-21 | 2004-09-02 | Translational Research Ltd. | 薬物の経鼻投与用組成物 |
| US8673360B2 (en) | 2004-08-10 | 2014-03-18 | Shin Nippon Biomedical Laboratories, Ltd. | Compositions that enable rapid-acting and highly absorptive intranasal administration |
| US7947308B2 (en) * | 2005-07-20 | 2011-05-24 | Raimar Loebenberg | Effervescent powders for inhalation |
| JP2009519972A (ja) * | 2005-12-15 | 2009-05-21 | アキュスフィア， インコーポレイテッド | 粒子ベースの経肺投与または経鼻投与用製薬の製造方法 |
| KR20080105174A (ko) * | 2006-04-03 | 2008-12-03 | 테바 파마슈티컬 인더스트리즈 리미티드 | 약물 미립자 |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| CN101668544B (zh) * | 2006-12-26 | 2013-04-24 | 株式会社新日本科学 | 经鼻投用制剂 |
| GB0716907D0 (en) | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
| WO2010033832A2 (en) * | 2008-09-19 | 2010-03-25 | Evestra, Inc. | Estriol formulations |
| EP2429495A4 (en) | 2009-05-15 | 2014-01-22 | Shin Nippon Biomedical Lab Ltd | INTRANASAL PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PHARMACOKINETICS |
| TWI695723B (zh) * | 2009-05-29 | 2020-06-11 | 美商沛爾醫療股份有限公司 | 用於經由呼吸道輸送活性劑的組成物以及相關方法與系統 |
| US20110262502A1 (en) | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| AU2011242457A1 (en) * | 2010-04-22 | 2012-11-08 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| JP2014504260A (ja) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
| EP2540281A1 (en) * | 2011-06-30 | 2013-01-02 | LEK Pharmaceuticals d.d. | Solid self-microemulsifying systems |
| CN105307639B (zh) | 2013-03-04 | 2020-06-30 | 博赏医药卢森堡责任有限公司 | 包含与载体颗粒结合的活性剂纳米颗粒的干药物组合物 |
-
2014
- 2014-03-03 CN CN201480011817.7A patent/CN105307639B/zh active Active
- 2014-03-03 DK DK14710757.7T patent/DK2964199T3/da active
- 2014-03-03 RS RS20200797A patent/RS60481B1/sr unknown
- 2014-03-03 PT PT147107577T patent/PT2964199T/pt unknown
- 2014-03-03 HU HUE14710757A patent/HUE050050T2/hu unknown
- 2014-03-03 WO PCT/US2014/019833 patent/WO2014137877A1/en active Application Filing
- 2014-03-03 BR BR112015021525-4A patent/BR112015021525B1/pt active IP Right Grant
- 2014-03-03 JP JP2015561494A patent/JP6564708B2/ja active Active
- 2014-03-03 AU AU2014226192A patent/AU2014226192B2/en active Active
- 2014-03-03 US US14/195,023 patent/US10695295B2/en active Active
- 2014-03-03 CA CA2901015A patent/CA2901015A1/en not_active Abandoned
- 2014-03-03 PL PL14710757T patent/PL2964199T3/pl unknown
- 2014-03-03 ES ES14710757T patent/ES2804702T3/es active Active
- 2014-03-03 SI SI201431571T patent/SI2964199T1/sl unknown
- 2014-03-03 RU RU2015141792A patent/RU2715714C2/ru active
- 2014-03-03 MX MX2015011624A patent/MX2015011624A/es active IP Right Grant
- 2014-03-03 LT LTEP14710757.7T patent/LT2964199T/lt unknown
- 2014-03-03 EP EP14710757.7A patent/EP2964199B1/en active Active
-
2015
- 2015-08-14 ZA ZA2015/05852A patent/ZA201505852B/en unknown
- 2015-08-26 IL IL240867A patent/IL240867B/en active IP Right Grant
-
2020
- 2020-06-25 CY CY20201100589T patent/CY1124635T1/el unknown
- 2020-06-25 US US16/911,598 patent/US10918601B2/en active Active
- 2020-07-14 HR HRP20201103TT patent/HRP20201103T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT2964199T (lt) | 2020-08-10 |
| AU2014226192B2 (en) | 2018-07-26 |
| SI2964199T1 (sl) | 2020-10-30 |
| ES2804702T3 (es) | 2021-02-09 |
| BR112015021525B1 (pt) | 2022-06-14 |
| BR112015021525A2 (pt) | 2017-07-18 |
| US20200390706A1 (en) | 2020-12-17 |
| HUE050050T2 (hu) | 2020-11-30 |
| US10918601B2 (en) | 2021-02-16 |
| MX2015011624A (es) | 2015-12-17 |
| CN105307639B (zh) | 2020-06-30 |
| AU2014226192A1 (en) | 2015-09-03 |
| HRP20201103T1 (hr) | 2021-02-05 |
| IL240867B (en) | 2020-11-30 |
| AU2014226192A8 (en) | 2016-04-21 |
| EP2964199A1 (en) | 2016-01-13 |
| ZA201505852B (en) | 2017-07-26 |
| RU2715714C2 (ru) | 2020-03-03 |
| EP2964199B1 (en) | 2020-04-22 |
| PT2964199T (pt) | 2020-05-12 |
| JP2016510742A (ja) | 2016-04-11 |
| US20140248367A1 (en) | 2014-09-04 |
| PL2964199T3 (pl) | 2021-01-25 |
| WO2014137877A1 (en) | 2014-09-12 |
| CN105307639A (zh) | 2016-02-03 |
| RU2015141792A3 (el) | 2018-03-01 |
| RU2015141792A (ru) | 2017-04-07 |
| RS60481B1 (sr) | 2020-08-31 |
| US10695295B2 (en) | 2020-06-30 |
| DK2964199T3 (da) | 2020-06-15 |
| IL240867A0 (en) | 2015-10-29 |
| JP6564708B2 (ja) | 2019-08-21 |
| CA2901015A1 (en) | 2014-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| CY1121373T1 (el) | Μεθοδος και φαρμακοτεχνικη μορφη για εισπνοη | |
| CY1123937T1 (el) | Σκευασμα ξηρης σκονης που περιλαμβανει ενα αντιχολινεργικο, ενα κορτικοστεροειδες και ενα βητα-αδρενεργικο για χορηγηση δια εισπνοης | |
| EA201492290A1 (ru) | Составы и способы для вагинальной доставки антипрогестинов | |
| EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
| BR112015004637A2 (pt) | derivados de imidazolina, métodos de preparação dos mesmos, e suas aplicações na medicina | |
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
| MX2015002299A (es) | Nanoparticula polimerica de finasterida, composicion acuosa que contiene la misma, composicion para el tratamiento de alopecia, metodo para preparar la composicion y su uso. | |
| CO7160008A2 (es) | Derivados de estra- 1,3,5(10),16- tetraeno 3-sustituidos, métodos para su preparación, prepara-ciones farmaceúticas que los contienen, así como su uso para la preparación de medicamentos | |
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| ECSP16084317A (es) | Formulaciones farmacéuticas, procesos para la preparación y métodos de uso | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
| CY1124893T1 (el) | Φαρμακευτικο μeιγμα μαροπιταντης | |
| EA201401309A1 (ru) | Фармацевтическая композиция для ингаляции, содержащая аклидиний, и её применение | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| MX364946B (es) | Sistema adyuvante mejorado para la administración de vacunas orales. | |
| MX2015010486A (es) | Composicion masticable para administracion oral y proceso para preparar la misma. | |
| WO2014165829A3 (en) | Nanoparticle formulations | |
| IN2013MU01177A (el) | ||
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. |